HC Wainwright & Co. Reiterates Buy on Xeris Biopharma Holdings, Maintains $6 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on Xeris Biopharma Holdings (NASDAQ:XERS) and maintained a price target of $6.
August 15, 2024 | 10:14 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on Xeris Biopharma Holdings and maintained a price target of $6.
The reiteration of a Buy rating and maintenance of a $6 price target by HC Wainwright & Co. is a positive signal for investors, likely boosting short-term confidence and stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100